Lilly’s retatrutide beats Ozempic on A1C and weight loss in head-to-head diabetes trial

Lilly’s retatrutide topped Ozempic on A1C and weight loss in an 80-week head-to-head trial; Artiva halts its AlloNK cell therapy after two patient deaths; FDA proposes a single BLA for individualized gene editing.